AUPH Aurinia Pharmaceuticals
- 7.210
- -0.110-1.50%
- 7.330
- +0.120+1.66%
Aurinia Pharmaceuticals News
Bloom Burton Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Raises Target Price to $9.4
Aurinia Pharmaceuticals: Strategic Growth and Buy Rating Amidst Japan Market Expansion and M&A Potential
Aurinia Pharmaceuticals Analyst Ratings
Aurinia Pharmaceuticals Price Target Maintained With a $10.00/Share by Cantor Fitzgerald
Aurinia Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Aurinia Pharmaceuticals, Maintains $13 Price Target
H.C. Wainwright Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $13
Buy Rating Affirmed for Aurinia Pharmaceuticals on AUR200's Clinical and Financial Promise
RBC Capital Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $8
Analysts Have Conflicting Sentiments on These Healthcare Companies: UniQure (QURE), Aurinia Pharmaceuticals (AUPH) and Vertex Pharmaceuticals (VRTX)
Aurinia Pharmaceuticals (AUPH) Receives a Buy From RBC Capital
H.C. Wainwright Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $13
TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $11
Aurinia Pharmaceuticals: Strong Q2 Sales and Market Penetration Back Buy Rating
RBC Capital Gives a Buy Rating to Aurinia Pharmaceuticals (AUPH)
Leerink Partners Keeps Their Buy Rating on Aurinia Pharmaceuticals (AUPH)
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), Aurinia Pharmaceuticals (AUPH) and 908 Devices (MASS)
HC Wainwright & Co. Reiterates Buy on Aurinia Pharmaceuticals, Maintains $13 Price Target
Aurinia Pharmaceuticals Analyst Ratings
Aurinia Pharmaceuticals: Strong Buy Rating Amidst Share Repurchase and Promising LUPKYNIS Prospects
Analysis
Price Target
No Data
No Data